Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash & Equivalents (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Cash & Equivalents data on record, last reported at $7.0 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 25.38% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $7.0 million, up 25.38%, while the annual FY2025 figure was $11.1 million, 68.54% up from the prior year.
  • Cash & Equivalents reached $7.0 million in Q4 2025 per INM's latest filing, down from $9.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $15.3 million in Q3 2021 and bottomed at $1.0 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $7.6 million, with a median of $6.9 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: crashed 89.35% in 2024, then skyrocketed 357.74% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $11.3 million in 2021, then increased by 1.53% to $11.5 million in 2022, then plummeted by 88.58% to $1.3 million in 2023, then surged by 326.84% to $5.6 million in 2024, then grew by 25.38% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $7.0 million in Q4 2025, $9.3 million in Q3 2025, and $11.1 million in Q2 2025.